Comparison

Cagrilintide (acetate) European Partner

Item no. HY-P3462A-1ea
Manufacturer MedChem Express
Amount 1 ea
Quantity options 10 mg 1 ea 1 mg 5 mg
Category
Type Inhibitors
Specific against other
Purity 99.81
Citations [1]Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021 Aug 12;64(15):11183-11194. <br/>[2]Fletcher MM, et al. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. J Pharmacol Exp Ther. 2021 Jun;377(3):417-440. <br/>[3]Dehestani B, et al. Amylin as a Future Obesity Treatment. J Obes Metab Syndr. 2021 Dec 30;30(4):320-325.
Smiles O=C(CC[C@H](NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H]1[C@@H](C)O)=O)C)=O)[C@@H](C)O)=O)CC(N)=O)=O)CSSC[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N2[C@H](C(N[C@H](C(N[C@H](C(N3[C@H](C(N4[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N5[C@H](C(N)=O)CCC5)=O)[C@@H](C)O)=O)CC(N)=O)=O)CO)=O)=O)C(C)C)=O)CC(N)=O)=O)[C@@H](C)O)=O)CCC4)=O)CCC3)=O)CC(C)C)=O)[C@H](CC)C)=O)CCC2)=O)=O)CC6=CC=CC=C6)=O)CC(N)=O)=O)CC(N)=O)=O)CO)=O)CO)=O)CC7=CNC=N7)=O)CCCNC(N)=N)=O)CC(C)C)=O)CC8=CC=CC=C8)=O)CCC(O)=O)=O)C)=O)CC(C)C)=O)CCCNC(N)=N)=O)CCC(N)=O)=O)[C@@H](C)O)=O)C)=O)NC1=O)=O)CCCCN.O=C(C)O.[x]
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Available
Product Description
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies[1][2][3].
StorageTemperature
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)
Shipping
Blue Ice
Manufacturers Applications
Metabolism-protein/nucleotide metabolism
MolecularWeight
4409.01 (free base)
Clinical Information
Phase 3
Manufacturers Research Area
Metabolic Disease
Solubility
DMSO : 100 mg/mL (ultrasonic)|H2O : 50 mg/mL (ultrasonic)
Target
CGRP Receptor
Manufacturers Target
CGRP Receptor
Manufacturers Pathway
GPCR/G Protein; Neuronal Signaling
Manufacturers Product type
Peptides

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 1 ea
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close